Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia
- PMID: 9165493
- DOI: 10.1016/S0893-133X(96)00276-X
Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia
Abstract
The dopamine (DA) hypothesis of schizophrenia, which was based largely on evidence that pharmacological manipulations of DA systems influence the symptoms of schizophrenia, is undergoing a transformation due to our knowledge of the anatomy and pharmacology of additional subtypes of dopamine receptors. New research links the multiplicity of D2-like receptors to divergent neuroanatomic sites of suspected pathology in schizophrenia. We hypothesize that this research suggests that D2 receptors in the basal ganglia are the likely site of extrapyramidal symptoms and not antipsychotic effects. Rather, D3 receptors of the mesolimbic system are a likely site of antipsychotic effects, and D2 and D4 receptors in the medial temporal lobe and limbic cortical areas are the sites of additional antipsychotic effects. This work also suggests that divergent DA receptor circuits are likely associated with the pathophysiology of this disorder.
Similar articles
-
Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes.J Psychiatr Res. 1997 Mar-Apr;31(2):197-217. doi: 10.1016/s0022-3956(96)00043-x. J Psychiatr Res. 1997. PMID: 9278186 Review.
-
The role of extrastriatal dopamine D2 receptors in schizophrenia.Biol Psychiatry. 2006 May 15;59(10):919-28. doi: 10.1016/j.biopsych.2006.01.022. Biol Psychiatry. 2006. PMID: 16682269 Review.
-
Dopamine receptor pharmacology.Curr Opin Neurol Neurosurg. 1993 Aug;6(4):602-8. Curr Opin Neurol Neurosurg. 1993. PMID: 8104554 Review.
-
Dopamine D4 receptors elevated in schizophrenia.Nature. 1993 Sep 30;365(6445):441-5. doi: 10.1038/365441a0. Nature. 1993. PMID: 8413587
-
Cortical microcircuits in schizophrenia--the dopamine hypothesis revisited.Pharmacopsychiatry. 2006 Feb;39 Suppl 1:S68-71. doi: 10.1055/s-2006-931498. Pharmacopsychiatry. 2006. PMID: 16508900
Cited by
-
Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.Curr Pharm Biotechnol. 2012 Jun;13(8):1535-42. doi: 10.2174/138920112800784899. Curr Pharm Biotechnol. 2012. PMID: 22283761 Free PMC article. Review.
-
Downregulated AKT-mTOR signaling pathway proteins in dorsolateral prefrontal cortex in Schizophrenia.Neuropsychopharmacology. 2020 May;45(6):1059-1067. doi: 10.1038/s41386-020-0614-2. Epub 2020 Jan 17. Neuropsychopharmacology. 2020. PMID: 31952070 Free PMC article.
-
Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride.Psychopharmacology (Berl). 2005 Aug;180(4):664-9. doi: 10.1007/s00213-005-2161-2. Epub 2005 Sep 14. Psychopharmacology (Berl). 2005. PMID: 15719226 Clinical Trial.
-
My Dream, My Rules: Can Lucid Dreaming Treat Nightmares?Front Psychol. 2019 Nov 26;10:2618. doi: 10.3389/fpsyg.2019.02618. eCollection 2019. Front Psychol. 2019. PMID: 31849749 Free PMC article. Review.
-
Functional Correlates of Striatal Dopamine Transporter Cerebrospinal Fluid Levels in Alzheimer's Disease: A Preliminary 18F-FDG PET/CT Study.Int J Mol Sci. 2023 Jan 1;24(1):751. doi: 10.3390/ijms24010751. Int J Mol Sci. 2023. PMID: 36614193 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical